Last reviewed · How we verify
NCT05862675
The Role and Mechanism of Immune Regulation in Acute Lung Injury in Children
trial testing RNA sequencing of blood samples in Acute Lung Injury. Withdrawn.
30 May 2026
Quick facts
| Lead sponsor | Children's Hospital of Chongqing Medical University |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 2 May 2023 |
| Primary completion | 30 May 2026 |
| Estimated completion | 30 May 2026 |
Drugs / interventions tested
- RNA sequencing of blood samples
Conditions studied
- Acute Lung Injury — all drugs for Acute Lung Injury →
Sponsor
Children's Hospital of Chongqing Medical University
Who can join
Adults 1 to 14, any sex, with Acute Lung Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute lung injury is a highly prevalent disease in children, posing a serious threat to their health and causing economic burden on society and families. It has received high attention. Blocking the cascade immune inflammatory response that occurs in the respiratory tract and finding key targets for the prevention and treatment of acute lung injury has become an important challenge faced by the medical community. The pathogenesis of acute lung injury is complex, involving the combined action of multiple cells and cytokines in the immune system. Therefore, it is necessary to further study the function of immune cells and specific immune pathogenesis, providing new ideas and theoretical basis for clinical treatment of acute lung injury. The omics technology includes Genomics, Transcriptome, proteomics, metabolomics, etc. Through qualitative and quantitative analysis of changes in low molecular weight molecules or metabolites of biological samples, it provides a new way to find biomarkers and pathogenesis. We plan to study the peripheral blood of children with acute lung injury and healthy children, and use network analysis to screen for differential genes and related enrichment pathways in acute lung injury. We aim to explore the correlation between immune regulation and inflammatory repair in children with acute lung injury, and analyze the regulatory mechanisms between immune cells related to it. Provide assistance for clinical diagnosis and treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05862675
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Lung Injury
Currently open trials in the same condition.
- NCT05704166 — PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients · Phase 2 · recruiting
Other Children's Hospital of Chongqing Medical University trials
Trials by the same sponsor.
- NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet · NA · recruiting
- NCT07472829 — Research on Speech Development Trajectories and Predictive Models in Children With Autism Spectrum Disorder · not yet recruiting
- NCT05911893 — the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children · NA · recruiting
- NCT06404294 — The External Diaphragm Pacemaker Assisted Extubation in Premature Infants With Invasive Mechanical Ventilation · NA · recruiting
- NCT05768399 — The Role of Biomarkers in the Occurrence and Development of Asthma · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05862675 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Children's Hospital of Chongqing Medical University
- Last refreshed: 11 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05862675.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing